Rationale for the development of an engineered sporozoite malaria vaccine

Adv Immunol. 1989:45:283-334. doi: 10.1016/s0065-2776(08)60695-1.

Authors

V Nussenzweig¹, R S Nussenzweig

Affiliation

¹ Department of Pathology, New York University Medical Center, New York 10016.

PMID: 2665440
DOI: 10.1016/s0065-2776(08)60695-1

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Animals
Antigens, Protozoan / genetics
Humans
Immunotherapy*
Malaria / immunology
Malaria / prevention & control*
Plasmodium / genetics
Plasmodium / growth & development
Plasmodium / immunology
T-Lymphocytes / immunology
Vaccines, Synthetic* / therapeutic use

Substances

Antigens, Protozoan
Vaccines, Synthetic